ABcann Global Stock (TSXV: ABCN) (OTC: ABCCF) - Investor Dashboard

➔ ABcann Global
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees:  34
Established: 2012
CEO: Barry Fishman


Fiscal Year-End: December
License Renewal Month: October 2017
Licenses: 1
Licensed Capacity:  625 kilograms
Number of Patients: na
Headquarters: Napanee, Ontario

Financials (09/30/17)

Cash on hand: $43.4mm
Fixed Investment: $8.3mm
Shareholders’ Equity: $35.2mm
Revenues – Last Quarter: $177K
Adj. Gross Margin : -571%
EPS : -.04

Capital Structure (11/27/17)

Last Financing: 6.666mm shares at $2.25
Basic Shares: 135.7mm
Warrants: 20.7mm
Options: 11.2mm
Diluted Shares: 187.3mm

Company Brief

Licensed since March 2014, ABcann sets itself apart from other Canadian licensed producers with its 94% customer retention rate, its focus on organic cultivation in proprietary growing chambers and its industry-leading  production yields in excess of 250 grams per sq. ft., double the industry average.

The company, which is in the process of developing its 65-acre site with a second 150K sq. ft. facility, has a research partnership with the University of Guelph and and has supplied innovative cannabis inhaler device maker Syqe Medical with its standardized cannabis.

Featured Video




  • Focus on pharmaceutical grade plant standardization
  • 94.7% customer retention rate
  • Organic production using exclusive, computer-controlled environmental system

Growth Strategy

  • Expand existing facility and construct 2nd facility targeting 40 kg/annum production capacity
  • Pursue global initiatives in Europe, Israel and Australia
  • Active discussions to license production to U.S. operators


  • Production through computer-controlled environmental systems
  • Industry-leading efficiency in terms of yield per square foot
  • Research partnership with University of Guelph

Exclusive Interview

Market One Media Interview

Above Industry Average Yields

ABcann’s standardized organic growing methods yield not only a higher quality product as reflected by its premium pricing but also a lower overall cost. According to PI Financial, ABcann is able to produce almost double the industry average as measured by grams per square foot.

Strong Advisory Board Led by
the “Father of Cannabis Medicine”

Raphael-Mechoulam-ABcannDr. Raphael Mechoulam is an Israeli organic chemist and professor of Medicinal Chemistry at the Hebrew University of Jerusalem in Israel. Mechoulam is best known for his work (together with Y. Gaoni) in the isolation, structure elucidation and total synthesis of Δ9-tetrahydrocannabinol, the main active principle of cannabis and for the isolation and the identification of the endogenous cannabinoids anandamide from the brain and 2-arachidonoyl glycerol (2-AG) from peripheral organs together with his students, postdocs and collaborators.


Institutional Analyst Coverage

Pi Financial

Mackie Research

Curated Stories & News

Visit ABcann Global, Inc.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. ABcann Global, Inc. is a client of NCV Media, LLC. Read our full disclaimer.